HACKENSACK, N.J.--(BUSINESS WIRE)--ReGen Biologics (OTC: RGBI) today announced the international release of a new brand name – MenaflexTM – for its collagen meniscus implant device and associated product web site, www.menaflex.com. “The CMI® name was used during the research and development phase of the Company’s collagen meniscus implant device, and it will continue to be seen in numerous scientific publications and clinical references. Now that we are marketing the product outside the United States, we will utilize a unique brand name that allows for improved recognition among patients and surgeons,” stated Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer.
